Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Mar 11, 2010

Premium

Title: RNAi Modulation of MLL-AF4 and Uses Thereof

Patent Number: 7,674,779

Filed: Feb. 27, 2008

Lead Inventor: Olaf Heidenreich, Alnylam Pharmaceuticals

"The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the down-regulation of MLL-AF4, by chemically modified oligonucleotides," the patent's abstract states.


Title: Compositions and Methods for siRNA Inhibition of Angiogenesis

Patent Number: 7,674,895

Filed: Sept. 8, 2006

Lead Inventor: Samuel Reich, University of Pennsylvania (Opko Health)

The patent, its abstract states, claims "RNA interference using small interfering RNAs … specific for the vascular endothelial growth factor gene and the VEGF receptor genes Flt-1 and Flk-1/KDR. … Diseases which involve angiogenesis stimulated by over-expression of VEGF, such as diabetic retinopathy, age-related macular degeneration, and many types of cancer, can be treated by administering the small interfering RNAs."


Title: siRNA Targeting BCL2L1

Patent Number: 7,674,896

Filed: Dec. 7, 2006

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."


Title: Nucleic Acid Compounds for Inhibiting Myc Gene Expression and Uses Thereof

Application Number: 20100055782

Filed: March 3, 2008 PCT Filed: March 3, 2008

Lead Inventor: Steven Quay, MDRNA

The invention, the patent application's abstract states, comprises "meroduplex ribonucleic acid molecules capable of decreasing or silencing Myc gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a Myc mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a Myc gene in a cell or in a subject to treat a Myc-related disease," the abstract adds.


Title: Nucleic Acid Compounds for Inhibiting Ras Gene Expression and Uses Thereof

Application Number: 20100055783

Filed: March 3, 2008 PCT Filed: March 3, 2008

Lead Inventor: Steven Quay, MDRNA

The invention, the patent application's abstract states, comprises "meroduplex ribonucleic acid molecules capable of decreasing or silencing Ras gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an H-Ras, K-Ras, or N-Ras mRNA. In addition, the meroduplex may have at least one uridine [substituted with] a 5-methyluridine, a nucleoside [substituted with] a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a Ras gene in a cell or in a subject to treat a Ras-related disease."


Title: Nucleic Acid Compounds for Inhibiting Wnt Gene Expression and Uses Thereof

Application Number: 20100055784

Filed: March 3, 2008 PCT Filed: March 3, 2008

Lead Inventor: Steven Quay, MDRNA

The patent application, its abstract states, claims "meroduplex ribonucleic acid molecules capable of decreasing or silencing WNT1, WNT2, or WNT3A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a WNT1, WNT2, or WNT3A mRNA. In addition, the meroduplex may have at least one uridine [substituted with] a 5-methyluridine, a nucleoside [substituted with] a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a WNT1, WNT2, or WNT3A gene in a cell or in a subject to treat a WNT1, WNT2, or WNT3A-related disease," according to the abstract.


Title: siRNA Targeting Coatomer Protein Complex, Subunit Beta 2

Application Number: 20100056395

Filed: Sept. 30, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to COPB2."


Title: Gene-Silencing Methods

Application Number: 20100058490

Filed: May 3, 2007 PCT Filed: May 3, 2007

Lead Inventor: Peter Waterhouse, Commonwealth Scientific and Industrial Research Organization

The patent application, its abstract states, claims "methods and means … to modulate gene silencing in eukaryotes through the alteration of the functional level of particular Dicer or Dicer-like proteins. Also provided are methods and means to modulate post-transcriptional gene silencing in eukaryotes through the alteration of the functional level of proteins involved in transcriptional silencing of the silencing RNA encoding genes."

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.